Who are Antiplatelet or Anticoagulant Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rivaroxaban and ticagrel therapy, Patent clopidogrel, Active Comparator: Aspirin+Clopidogrel, Clopidogrel with aspirin, Aspirin and clopidogrel/Ticagrelor, CYP2C19 genotype guided P2Y12 monotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antiplatelet-or-anticoagulant-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Antiplatelet or Anticoagulant Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antiplatelet or Anticoagulant Therapy (Antiplatelet or Anticoagulant Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet. Area: Cardiovascular.

phase 1 Antiplatelet P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Antiplatelet or Anticoagulant Therapy (Antiplatelet or Anticoagulant Therapy) — Syntrillo, Inc. Inhibits platelet aggregation

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Antiplatelet or Anticoagulant Therapy TARGET	Antiplatelet or Anticoagulant Therapy	Syntrillo, Inc	phase 1	Antiplatelet	P2Y12 receptor
rivaroxaban and ticagrel therapy	rivaroxaban and ticagrel therapy	Beijing Anzhen Hospital	marketed	Anticoagulant and antiplatelet combination therapy	Factor Xa (rivaroxaban); P2Y12 receptor (ticagrelor)
Patent clopidogrel	Patent clopidogrel	Hospital Central San Luis Potosi, Mexico	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Active Comparator: Aspirin+Clopidogrel	Active Comparator: Aspirin+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)
Clopidogrel with aspirin	Clopidogrel with aspirin	University of Florida	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Aspirin and clopidogrel/Ticagrelor	Aspirin and clopidogrel/Ticagrelor	Beijing Neurosurgical Institute	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
CYP2C19 genotype guided P2Y12 monotherapy	CYP2C19 genotype guided P2Y12 monotherapy	St. Antonius Hospital	marketed	P2Y12 inhibitor (antiplatelet agent)	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet class)

Korea University Guro Hospital · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Syntrillo, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiplatelet or Anticoagulant Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/antiplatelet-or-anticoagulant-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab